Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
The Lancet. Child & Adolescent Health|July 17, 2021
Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort studyStephen T J Ray, Omar Abdel-Mannan, Mario Sa, et al.
Neurology|July 19, 2022
Natural History Study of STXBP1-Developmental and Epileptic Encephalopathy Into AdulthoodHannah Stamberger, David Crosiers, Ganna Balagura, et al.
Brain Communications|August 19, 2021
Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance studyAmy L Ross Russell, Marc Hardwick, Athavan Jeyanantham, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Frontiers in Cell and Developmental Biology|December 26, 2022
The different clinical facets of <i>SYN1</i>-related neurodevelopmental disordersIlaria Parenti, Elsa Leitão, Alma Kuechler, et al.
Neurology|November 11, 2018
Neurologic phenotypes associated with <i>COL4A1</i>/<i>2</i> mutations: Expanding the spectrum of diseaseSara Zagaglia, Christina Selch, Jelena Radic Nisevic, et al.
Neurology|February 10, 2019
Clinical spectrum of <i>STX1B</i>-related epileptic disordersStefan Wolking, Patrick May, Davide Mei, et al.
Neurology|July 22, 2025
Development and Adaptive Function in Individuals With <i>SCN2A</i>-Related DisordersBeatrice Southby Goad, Jill Rodda, Meagan Allen, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Pageof 18